Seruma šķīstošā interleikīna 2 receptora alfa (sIL-R2α) un CA-125 kombinētais tests olnīcu vēža diagnostikai

Simple item page
dc.contributor.authorMačuks, Ronalds
dc.contributor.authorBaidekalna, Ieva
dc.contributor.authorNuķe, Inta
dc.contributor.authorDoniņa, Simona
dc.contributor.institutionRīga Stradiņš University
dc.contributor.institutionInstitute of Microbiology and Virology
dc.date.accessioned2021-08-18T08:45:01Z
dc.date.available2021-08-18T08:45:01Z
dc.date.issued2011-01-01
dc.description.abstractDetection of ovarian cancer can be improved using a combined diagnostic test consisting of Ca-125 and serum interleukine-2 receptor alpha (sIL-R2α) at a particular threshold. The objective of the study was to evaluate the accuracy of a diagnostic marker assay that combined Ca-125 and serum interleukine-2 receptor alpha. A case-control study of 38 patients with ovarian cancer, 40 patients with benign ovarian diseases and 31 age-matched healthy controls was designed. Ca-125 and sIL-2Rα were detected in patients' serum by standardized chemiluminescent immunometric assays. For Ca-125, a standard cutoff level of 21 U/ml was applied and for sIL-R2α - two cutoff levels were calculated from women included in the control group - one as a mean concentration and the other as an upper limit of a 95% confidence interval. Mean serum concentrations among ovarian cancer patients for CA125 and sIL-2Rα were 265.9 ± 40.2 U/ml and 651.0 ± 50.5 U/ml, respectively. The upper limit of the 95% confidence interval for a healthy control group of women was 304.5 U/ml for sIL-2Rα. Sensitivity and specificity of 89.4% and 85.9% was achieved when CA125 was combined together with sIL-2Rα at a threshold of 304.5U/ml with the condition that both markers are elevated. Sensitivity and specificity of 92.5% and 88.4% was observed when both biomarkers were applied to menopausal women. Serum sIL-2Rα in combination with CA125 can be used as a differential diagnostic test for ovarian cancer at a specific threshold, especially among menopausal women.en
dc.description.statusPeer reviewed
dc.format.extent6
dc.format.extent118628
dc.identifier.citationMačuks, R, Baidekalna, I, Nuķe, I & Doniņa, S 2011, 'Seruma šķīstošā interleikīna 2 receptora alfa (sIL-R2α) un CA-125 kombinētais tests olnīcu vēža diagnostikai', Proceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences, vol. 65, no. 1-2, pp. 7-12. https://doi.org/10.2478/v10046-011-0012-6
dc.identifier.doi10.2478/v10046-011-0012-6
dc.identifier.issn1407-009X
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/6034
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=80054757238&partnerID=8YFLogxK
dc.language.isolav
dc.relation.ispartofProceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCa125
dc.subjectdiagnostics
dc.subjectinterleukine-2 receptor alpha
dc.subjectovarian cancer
dc.subjectscreening
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectGeneral
dc.subjectSDG 3 - Good Health and Well-being
dc.titleSeruma šķīstošā interleikīna 2 receptora alfa (sIL-R2α) un CA-125 kombinētais tests olnīcu vēža diagnostikailv
dc.title.alternativeRole of a combined soluble interleukine-2 receptor alpha (sIL-R2α) and CA-125 serum marker assay for detection of ovarian canceren
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Role_of_a_combined_soluble_interleukine.pdf
Size:
115.85 KB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure